

AMENDMENTS TO THE CLAIMS

1. (Cancelled)
2. (Currently amended) A method of inhibiting an antigen-specific response of ~~an immune system~~ a T cell to subsequent presentation of said antigen, comprising administering to said ~~immune system~~ T cell an effective amount of exogenous interleukin-10 and said antigen.
3. (Currently amended) The method of Claim 2:
 - a) wherein said ~~immune~~ T cell response is mediated by a macrophage, APC, langerhans cell, or dendritic cell;
 - b) further inhibiting proliferative response of CD4+ host-reactive T cell clones; or
 - c) wherein said inhibiting persists for at least about 21 days.
4. (Original) The method of Claim 2, wherein said effective amount is sufficient to decrease responder T cell activation.
5. (Currently amended) The method of Claim 4, further comprising reduced T cell-stimulatory capacity of peripheral blood mononuclear cells, dendritic cells, monocytes, and/or normal B cells.
- 6-14. (Cancelled)
15. (Previously amended) A method of suppressing ~~an immune response of a T cell~~ response to an antigen, comprising administering to said T cell a combination of:
 - a) IL-10; and

b) either said antigen or anti-CD3 antibodies.

16. (Original) The method of Claim 15, wherein said antigen is alloantigen or self antigen.

17. (Original) The method of Claim 16, wherein said antigen is restricted by MHC molecules.

18. (Original) The method of Claim 15, performed in vivo.

19. (Currently amended) The method of Claim 15, which further comprising suppressing a T cell response to subsequent stimulation to [said T cell with] said antigen.

20. (Currently amended) The method of Claim 19, wherein said response to subsequent stimulation accompanies tissue transplantation.

21. (Original) The method of Claim 20, wherein said tissue is an organ or bone marrow.

22. (Original) The method of Claim 20, wherein said T cell is from the recipient of said tissue transplantation.

23. (Original) The method of Claim 15, wherein said response accompanies tissue transplantation and:

a) said administering is prior to said tissue transplantation;

b) said T cell is introduced to the recipient of said tissue transplantation; or

c) IL-10 is administered to the tissue to be transplanted before said transplantation.

24. (Original) The method of Claim 16, wherein said antigen causes an autoimmune disease.

25. (Currently amended) A method of suppressing a subsequent response ~~in~~of a T cell to an antigen, comprising administering to ~~an immune system~~ a T cell ~~comprising said cell~~ with a combination of:

- a) exogenous IL-10; and
- b) either antigen or anti-CD3 antibodies.

26. (Original) The method of Claim 25, wherein said IL-10 is administered for at least about 7 days.

27. (Currently amended) A method of inducing in T cell anergy to an MHC antigen, comprising administering to a T cell precursor ~~to said T cell~~;

- a) exogenous IL-10 and said antigen; or
- b) exogenous IL-10 and an anti-CD3.

28-30. (Cancelled)